Testing margins during surgery for junction cancer
Part of Cancer, Digestive system clinical trials.
This study compares ways to check the edges of removed tissue during surgery for a type of stomach and esophagus cancer. The goal is to make sure all cancer is removed, which may help lower the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of cancer where the stomach meets the esophagus (called esophagogastric junction adenocarcinoma, types II or III).
- Your cancer is at an early stage (cT1) or more advanced stage (cT2 or higher).
- You are planning to have surgery to remove the cancer.
- You are not allergic to the blue dye (methylene blue) or another dye (fluorescein sodium) used in the study.
- You do not have serious heart or blood vessel problems that would make surgery unsafe.
- You have not taken part in any other research drug or device study in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies blood-based biomarkers to help doctors choose the best individualized surgical treatment for gastroesophageal junction adenocarcinoma. If you qualify, you’ll get standard care plus additional testing to see whether the blood results can guide surgery more precisely.
This trial compares two surgical techniques for treating a specific type of cancer at the junction of the stomach and esophagus. It aims to find which surgery offers better outcomes for patients.
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
This trial tests a combination of three drugs—tislelizumab (immunotherapy), anlotinib (targeted therapy), and a chemotherapy regimen (S1 plus oxaliplatin)—given before surgery for locally advanced adenocarcinoma of the gastroesophageal junction. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
This trial tests a new imaging system that helps surgeons see if cancer cells remain after breast-conserving surgery. It may reduce the need for a second surgery by giving real-time feedback on the removed tissue.
Hear when a new Adenocarcinoma of the Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.